Brief: Shandong Boan Biotechnology Says Got Approval For Clinical Trial of BA1301 In China
09/01/2023 08:57
Jan 9 (Reuters) - Shandong Boan Biotechnology Co Ltd
6955.HK :
* APPROVAL OBTAINED FOR INITIATING CLINICAL TRIAL FOR
INNOVATIVE
ADC CANDIDATE BA1301 FOR INJECTION IN CHINA
Source text for Eikon: ID:
Further company coverage: 6955.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shandong Boan Biotechnology
See all newsBrief: Shandong Boan Biotechnology Says CDE Clears IND Application For BA1203
Brief: Shandong Boan Biotechnology Co Says Industrial Bank Financial Leasing Will Purchase Leased Assets From Co
Brief: Shandong Boan Biotechnology Announces CDE IND Application Acceptance For TLLA/IL-23 Bispecific Antibody BA2201
Brief: Shandong Boan Biotechnology Expects Net Loss Attributable Of RMB79 Million-RMB89 Million
Brief: Shandong Boan Biotechnology Submits BLA For BA9101 To Anvisa In Brazil